Literature DB >> 27558732

Ceftriaxone pretreatment reduces the propensity of postpartum depression following stroke during pregnancy in rats.

Yonghong Guan1, Xianying Liu2, Yuetian Su3.   

Abstract

OBJECTIVE: Ischemic stroke increases the propensity to develop depression in humans and laboratory animals, and we hypothesized that such an incidence during pregnancy may increase the risk for the development of postpartum depression (PPD).
MATERIALS AND METHODS: To test this hypothesis, we used bilateral common carotid arteries occlusion (BCCAO) to induce transient cerebral ischemia in pregnant rats, and evaluated its effects on subsequent development of PPD in dams. Additionally, we investigated whether ceftriaxone pretreatments before the induction of brain ischemia could alter the propensity of PPD.
RESULTS: We found that 15min BCCAO during pregnancy enhanced immobility time and reduced the frequency of swimming or climbing behaviors in the forced swim test, and decreased the sucrose preference in dams at postpartum day 21. Such behavioral alterations were associated with lower level of GLT-1 expression in the medial prefrontal cortical regions (mPFC) of PPD dams. Specifically, mPFC GLT-1 expression levels in dams with ischemia history were correlated with sucrose preference levels at postpartum day 21. Finally, ceftriaxone pretreatment (200mg/kg/day, 5days) before the 15min BCCAO prevented the development of PPD, and prevented the reduction of GLT-1 expression in the mPFC.
CONCLUSIONS: Taken together, our results suggested that ceftriaxone pretreatment before brain ischemia during pregnancy may reduce the propensity for the development of PPD by preventing the loss of GLT-1 expression in the mPFC.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Ceftriaxone; Glutamate transporter; Ischemia; Medial prefrontal cortex; Postpartum depression

Mesh:

Substances:

Year:  2016        PMID: 27558732     DOI: 10.1016/j.neulet.2016.08.036

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

Review 1.  Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation.

Authors:  Osama A Abulseoud; Fawaz Alasmari; Abdelaziz M Hussein; Youssef Sari
Journal:  Front Neurosci       Date:  2022-07-05       Impact factor: 5.152

Review 2.  EAAT2 as a Research Target in Bipolar Disorder and Unipolar Depression: A Systematic Review.

Authors:  Caren J Blacker; Vincent Millischer; Lauren M Webb; Ada M C Ho; Martin Schalling; Mark A Frye; Marin Veldic
Journal:  Mol Neuropsychiatry       Date:  2019-07-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.